BioSyent (RX.V) Aandeel Koers
BioSyent Koers
De omzet is de afgelopen 19 jaar met 19,3% per jaar gegroeid tot 43,05 Miljoen CAD. De winst per aandeel is de afgelopen 19 jaar met 18,6% per jaar gegroeid. De nettowinstmarge van BioSyent ligt op 20,9% en is ten opzichte van 21,9% enkele jaren eerder gedaald. BioSyent biedt momenteel een dividendrendement van circa 1,12%. De uitkeringsratio ligt rond 25% van de winst. Het dividend is de afgelopen 3 jaar met 71,0% per jaar gegroeid. Analisten hanteren een mediaan koersdoel van 16,83 CAD — dat impliceert 6,0% onder de huidige koers. Van de 7 analisten geven 6 het aandeel een koopadvies — per saldo een Kopen-consensus.
BioSyent aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
BioSyent bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over BioSyent
The business model of Biosyent Inc is focused on acquiring or in-licensing pharmaceutical and healthcare products. The company identifies niche markets with unmet medical needs and seeks regulatory approval to provide branded pharmaceuticals or health products that address those needs. Biosyent Inc aims to improve patient outcomes by offering innovative and effective treatment options in areas such as cardiovascular health, dermatology, neurology, and pediatrics. By partnering with established companies or acquiring the rights to specific products, Biosyent Inc brings affordable and quality medicines to market, providing patients with improved access to vital healthcare solutions.
Biosyent Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biosyent Inc in the market include pharmaceutical companies like Apotex Inc, Teva Pharmaceutical Industries Ltd, and Mylan N.V.
Biosyent Inc is a pharmaceutical company based in Canada. It was founded in 2004 and has since become a leader in the specialty pharmaceutical industry. The company focuses on acquiring or in-licensing niche pharmaceutical products, with a goal to provide reliable and effective therapeutic options to patients and healthcare professionals. Biosyent Inc has a successful track record of commercializing pharmaceutical products and has established a strong presence in the Canadian market. With a commitment to high-quality medications, Biosyent Inc continuously strives to meet the evolving healthcare needs of the population.
Biosyent Inc has achieved significant milestones since its inception. The company has successfully launched and commercialized multiple pharmaceutical and healthcare products in Canada. This includes obtaining regulatory approvals for important drugs, expanding their product portfolio, and establishing strategic partnerships with global pharmaceutical companies. Biosyent Inc has also demonstrated consistent revenue growth and increased market share, highlighting its strong performance in the industry. With their commitment to innovation and delivering high-quality products, Biosyent Inc continues to contribute to the advancement of healthcare and pharmaceuticals.
Biosyent Inc is primarily present in Canada and the United States.
Biosyent Inc is a pharmaceutical company that values innovation, sustainability, and customer-centricity. Their corporate philosophy revolves around providing high-quality, niche pharmaceutical products to meet the evolving healthcare needs of patients. With a focus on sourcing and licensing unique product opportunities, Biosyent Inc has built a strong reputation as a reliable partner within the healthcare industry. By utilizing their expertise in regulatory affairs and product commercialization, Biosyent Inc strives to improve patient outcomes while delivering value to their shareholders.
Analisten hanteren momenteel een gemiddeld koersdoel van 16,83 CAD voor het aandeel BioSyent (mediaan: 16,83 CAD), oftewel -6,0 % ten opzichte van de laatste koers. De consensus is gebaseerd op 7 analistenratings.
7 analisten beoordelen het aandeel BioSyent momenteel: 6 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat BioSyent een omzet van 73,20 Miljoen CAD en winst per aandeel van 1,05 CAD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel BioSyent op 11,29 EUR (17,90 CAD).
Het aandeel BioSyent (RX.V) is genoteerd aan 2 beurzen, waaronder: Toronto (RX.V).
Biosyent Inc is a pharmaceutical company headquartered in Canada that focuses on the development, marketing, and distribution of innovative products. The company specializes in medications in the areas of dermatology, gastroenterology, urology, and pain management. The business strategy of Biosyent Inc is to bring new products to the market that are needed by the growing number of patients and healthcare providers. In addition, the company also produces generics, which it offers at lower costs than the originals. Biosyent Inc aims to improve the lives of patients through better healthcare solutions. The company is active in various regions and works with partners in Canada, the US, and Europe. Through targeted investments and marketing initiatives, Biosyent Inc has managed to expand its reach and diversify its offerings. The company collaborates closely with physicians, pharmacies, and customers to tailor its offerings to their needs. In the field of dermatology, the company offers preparations for acne, eczema, psoriasis, and other skin problems. In gastroenterology, Biosyent Inc has developed medications that can be used to treat gastrointestinal diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. In urology, the company offers a solution for erectile dysfunction, and in pain management, it provides effective opioid antagonists in the form of nasal sprays and sublingual tablets. In addition to pharmaceutical products, Biosyent Inc also offers diagnostics and a solution for measuring urine flow. To further improve its products, the company also invests in researching new technologies and therapy forms. The company has a strong research and development department that works closely with the marketing and sales departments. Biosyent Inc strategically invests in the search for new active ingredients and solutions to continue offering its customers innovative products. Furthermore, the company works on optimizing its production processes and increasing its efficiency. The divisions of Biosyent Inc include: - Dermatology - Gastroenterology - Urology - Pain management Biosyent Inc. focuses on diversifying its offerings and producing innovative products that meet the needs of patients. Through the use of new technologies and procedures, the company aims to continue growing and strengthening its position in the market.
De verwachte omzet van BioSyent bedraagt 73,20 Miljoen CAD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van BioSyent bedraagt 11,81 Miljoen CAD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van BioSyent bedraagt momenteel 17,07. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het BioSyent-aandeel in te schatten.
De koers-omzetverhouding (P/S) van BioSyent bedraagt momenteel 2,75. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het BioSyent-aandeel.
De Eulerpool Kwaliteitsscore voor BioSyent is 10/10.
De ISIN van BioSyent is CA0906901081. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van BioSyent is A1J6DY. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van BioSyent is RX.V. Onder dit beurstickersymbool wordt het BioSyent-aandeel op de beurs verhandeld.
BioSyent aandeel
BioSyent Peer Group
BioSyent Ticker
BioSyent FIGI
Alle fundamentals en diepgaande analyse van BioSyent
Onze aandelenanalyse van het BioSyent-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van BioSyent. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: